Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.


Journal

Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479

Informations de publication

Date de publication:
05 2019
Historique:
received: 03 07 2018
accepted: 11 09 2018
pubmed: 13 11 2018
medline: 26 12 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

Congenital fibrinogen disorders are caused by variants occurring within the fibrinogen gene cluster. We describe ten subjects with disease-causative variants, adding information on such disorders. Ten subjects were referred to our Centre because of likely hypo/dysfibrinogenaemia. We evaluated the function and quantity of fibrinogen, using Clauss and immunoreactive assays, and performed genetic investigations by direct sequencing of alpha, beta and gamma chain-encoding genes. Mutations were analysed using SIFT and Polyphen-2 algorithms. We identified one afibrinogenaemic patient (alpha p.Arg178* homozygote) with bleeding/thrombotic events, three heterozygous patients with hypo/dysfibrinogenaemia (gamma p.Thr47ILeu combined with beta IVS7+1G>T; beta p.Cys95Ser; beta p.Arg196Cys) referred for bleeding or thrombotic episodes and six heterozygous subjects with hypofibrinogenaemia (alpha p.Glu41Lys; gamma p.Gly191Val; beta p.Gly288Ser; gamma p.His333Arg; gamma p.Asp342Glu and p.343-344 duplication; gamma p.Asp356Val), of whom four were symptomatic. Five novel missense changes and one novel duplication variant were found, all in hypofibrinogenaemic subjects: p.Glu41Lys (SIFT score 0, Polyphen-2 score 0.986) was identified in a woman with bleeding after major orthopaedic surgery; p.Gly191Val (SIFT score 0.02, Polyphen-2 score 1) in an asymptomatic woman; p.His333Arg (SIFT score 0, Polyphen-2 score 1) in a woman with a post-partum haemorrhage; and p.Asp342Glu (SIFT score 0.23, Polyphen-2 score 0.931); and an Asn-343 and Asp-344 duplication in a child who developed a haematoma following a fall. All but one of the novel mutations were in symptomatic subjects and are predicted to be deleterious. Our findings shed more light on genotype-phenotype relationships in congenital fibrinogen disorders.

Sections du résumé

BACKGROUND
Congenital fibrinogen disorders are caused by variants occurring within the fibrinogen gene cluster. We describe ten subjects with disease-causative variants, adding information on such disorders.
MATERIALS AND METHODS
Ten subjects were referred to our Centre because of likely hypo/dysfibrinogenaemia. We evaluated the function and quantity of fibrinogen, using Clauss and immunoreactive assays, and performed genetic investigations by direct sequencing of alpha, beta and gamma chain-encoding genes. Mutations were analysed using SIFT and Polyphen-2 algorithms.
RESULTS
We identified one afibrinogenaemic patient (alpha p.Arg178* homozygote) with bleeding/thrombotic events, three heterozygous patients with hypo/dysfibrinogenaemia (gamma p.Thr47ILeu combined with beta IVS7+1G>T; beta p.Cys95Ser; beta p.Arg196Cys) referred for bleeding or thrombotic episodes and six heterozygous subjects with hypofibrinogenaemia (alpha p.Glu41Lys; gamma p.Gly191Val; beta p.Gly288Ser; gamma p.His333Arg; gamma p.Asp342Glu and p.343-344 duplication; gamma p.Asp356Val), of whom four were symptomatic. Five novel missense changes and one novel duplication variant were found, all in hypofibrinogenaemic subjects: p.Glu41Lys (SIFT score 0, Polyphen-2 score 0.986) was identified in a woman with bleeding after major orthopaedic surgery; p.Gly191Val (SIFT score 0.02, Polyphen-2 score 1) in an asymptomatic woman; p.His333Arg (SIFT score 0, Polyphen-2 score 1) in a woman with a post-partum haemorrhage; and p.Asp342Glu (SIFT score 0.23, Polyphen-2 score 0.931); and an Asn-343 and Asp-344 duplication in a child who developed a haematoma following a fall.
DISCUSSION
All but one of the novel mutations were in symptomatic subjects and are predicted to be deleterious. Our findings shed more light on genotype-phenotype relationships in congenital fibrinogen disorders.

Identifiants

pubmed: 30418131
pii: 2018.0123-18
doi: 10.2450/2018.0123-18
pmc: PMC6596374
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

247-254

Références

Semin Thromb Hemost. 2009 Jun;35(4):356-66
pubmed: 19598064
Semin Thromb Hemost. 2016 Jun;42(4):356-65
pubmed: 27019463
Blood. 1986 Jun;67(6):1751-6
pubmed: 3708159
Blood. 2002 Dec 15;100(13):4478-84
pubmed: 12393540
Semin Thromb Hemost. 2013 Sep;39(6):585-95
pubmed: 23852822
J Biol Chem. 1985 Aug 15;260(17):9713-9
pubmed: 3160702
Blood. 2001 Jul 15;98(2):351-7
pubmed: 11435303
Nature. 1997 Oct 2;389(6650):455-62
pubmed: 9333233
Ann Intern Med. 1998 Jul 15;129(2):89-93
pubmed: 9669991
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Thromb Res. 1999 Dec 1;96(5):399-405
pubmed: 10605955
Haemophilia. 2013 Jul;19(4):611-8
pubmed: 23560673
J Thromb Haemost. 2006 Oct;4(10):2115-29
pubmed: 16999847
J Thromb Haemost. 2017 May;15(5):876-888
pubmed: 28211264
Blood. 2000 Oct 1;96(7):2501-5
pubmed: 11001903
J Thromb Haemost. 2010 Sep;8(9):2063-5
pubmed: 20626619
Blood. 2015 Mar 26;125(13):2052-61
pubmed: 25712993
Blood Coagul Fibrinolysis. 2006 Jun;17(4):235-40
pubmed: 16651864
Am J Hematol. 2000 Mar;63(3):149-55
pubmed: 10679806
J Thromb Haemost. 2004 Dec;2(12):2194-9
pubmed: 15613026
Blood. 2000 Nov 15;96(10):3473-9
pubmed: 11071644
Blood. 2001 Aug 1;98(3):661-6
pubmed: 11468164
Thromb Res. 1997 May 15;86(4):301-16
pubmed: 9187018

Auteurs

Elena Chinni (E)

Atherosclerosis and Thrombosis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

Giovanni Tiscia (G)

Atherosclerosis and Thrombosis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

Giovanni Favuzzi (G)

Atherosclerosis and Thrombosis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

Filomena Cappucci (F)

Atherosclerosis and Thrombosis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

Giuseppe Malcangi (G)

Department of Interdisciplinary Medicine, University of Bari, Bari, Italy.

Rossana Bagna (R)

Neonatology and Neonatal Intensive Care Unit, University Hospital, "Città della Salute e della Scienza", Turin, Italy.

Claudia Izzi (C)

Department of Obstetrics and Gynaecology, University of Brescia, Brescia, Italy.

Domenica Rizzi (D)

Department of Paediatric and Neonatal Pathology, Marche Nord Hospital, Pesaro, Italy.

Valerio De Stefano (V)

Institute of Haematology, Catholic University, Rome, Italy.

Elvira Grandone (E)

Atherosclerosis and Thrombosis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH